Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian experience.

[1]  A. Íñiguez,et al.  A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. , 2015, Journal of the American College of Cardiology.

[2]  Antonio Colombo,et al.  Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  P. Serruys,et al.  A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.

[4]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  A. Colombo,et al.  Early results following everolimus-eluting bioresorbable vascular scaffold implantation for the treatment of in-stent restenosis. , 2014, International journal of cardiology.

[6]  A. Íñiguez,et al.  A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). , 2014, Journal of the American College of Cardiology.

[7]  M. Joner,et al.  Drug-coated balloon therapy in coronary and peripheral artery disease , 2014, Nature Reviews Cardiology.

[8]  R. Virmani,et al.  Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. , 2013, European heart journal.

[9]  A. Kastrati,et al.  Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial , 2013, The Lancet.

[10]  B. Cortese,et al.  Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. , 2012, International journal of cardiology.

[11]  J. Brachmann,et al.  A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. , 2012, Journal of the American College of Cardiology.

[12]  H. Hirayama,et al.  Management of drug-eluting stent restenosis. , 2012, The Journal of invasive cardiology.

[13]  I. Seong,et al.  Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. , 2012, Journal of the American College of Cardiology.

[14]  A. Chieffo,et al.  Stent Thrombosis: Incidence, Predictors and New Technologies , 2012, Thrombosis.

[15]  R. Whitbourn,et al.  Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography. , 2011, JACC. Cardiovascular interventions.

[16]  J. Ako,et al.  [Everolimus-eluting stent]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[17]  Bernard Chevalier,et al.  Comparison of in vivo acute stent recoil between the bioresorbable everolimus‐eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus‐eluting stent , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  P. Serruys,et al.  Delineating the Numerous Causes of Drug-Eluting Stent Restenosis , 2011 .

[19]  T. Maruo,et al.  Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[20]  A. Colombo,et al.  Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[21]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[22]  G. Dehmer,et al.  Drug-eluting coronary artery stents. , 2009, American family physician.

[23]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial , 2008, The Lancet.

[24]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[25]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[26]  G. Mancini,et al.  Quantitative coronary angiography , 1994 .